[Systematic lupus erythematosus and antiphospholipid syndrome during pregnancy]

Z Rheumatol. 2006 May;65(3):192-4, 196-9. doi: 10.1007/s00393-006-0058-z.
[Article in German]

Abstract

Women with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are subject to several complications during pregnancy, including reactivation of SLE, thrombosis, miscarriage, neonatal lupus, pregnancy-induced hypertension, pulmonary hypertension and drug toxicity. Correct management of these patients requires combined medical-obstetric care, close surveillance of baby's growth and well-being, control of SLE activity and correct thromboprophylaxis. With good care, most pregnancies in women with SLE and APS end successfully.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Antiphospholipid Syndrome / diagnosis*
  • Antiphospholipid Syndrome / drug therapy
  • Antiphospholipid Syndrome / immunology
  • Aspirin / adverse effects
  • Aspirin / therapeutic use
  • Disease Progression
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Infant, Newborn
  • Lupus Erythematosus, Systemic / diagnosis*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / immunology
  • Pregnancy
  • Pregnancy Outcome
  • Risk Factors
  • Thrombophilia / diagnosis
  • Thrombophilia / drug therapy
  • Thrombophilia / immunology

Substances

  • Anticoagulants
  • Immunosuppressive Agents
  • Aspirin